Vertex seeks partner for flu drug after positive trial
This article was originally published in Scrip
Vertex Pharmaceuticals said an experimental flu drug worked in a Phase II trial and the company will seek a partner to help take the therapy into late-stage studies for possible market approval.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.